Safe Access: Trial With RemovAid Device

NCT ID: NCT04120337

Last Updated: 2021-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-23

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized trial will compare different approaches to removing a subdermal contraceptive implant from the upper arm of 225 women in Uganda. The experimental approach is a hand-held device (RemovAid) that incises the skin and grasps the implant for extraction. Safety and efficacy endpoints will be compared to the traditional removal approach (scalpel, forceps, tweezers).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial assigns participants to one of three arms: RemovAid+lidocaine patch (n=75), RemovAid+lidocaine injection (n=75) or traditional approach+lidocaine injection(n=75). Complication rates in the different arms will be compared. Efficacy (successful implant removal) will be the secondary comparisons. Finally, pain during removal and duration of removal procedure will be compared. Participants will return to the clinic within 4 weeks of the removal procedure to record the healing process and final interventions (if any).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Removal of a Contraceptive Subdermal Implant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RemovAid Device + lidocaine patch

Test device with lidocaine patch for local anesthesia

Group Type EXPERIMENTAL

RemovAid device + lidocaine patch

Intervention Type DEVICE

The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.

RemovAid Device + lidocaine injection

Test device with lidocaine injection for local anesthesia

Group Type EXPERIMENTAL

RemovAid device + lidocaine injection

Intervention Type DEVICE

The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.

Standard removal technique + lidocaine injection

Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia

Group Type ACTIVE_COMPARATOR

Standard technique + lidocaine injection

Intervention Type PROCEDURE

Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RemovAid device + lidocaine patch

The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.

Intervention Type DEVICE

Standard technique + lidocaine injection

Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.

Intervention Type PROCEDURE

RemovAid device + lidocaine injection

The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* seeking voluntary removal of a one-rod subdermal implant
* willing to sign an informed consent document
* willing to be randomized to the new device vs. standard technique
* willing to follow-up at the study clinic for any subsequent removal-related complications
* willing to have any follow-up complications recorded and shared
* has an implant that is completely and easily palpable
* has an implant that is easily pinched and lifted
* no known allergies to skin preparation products or local anesthetics

Exclusion Criteria

* Implants that are not easily palpable
* Previous failed implant removal
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karolinska Institutet

OTHER

Sponsor Role collaborator

Mulago Hospital, Uganda

OTHER

Sponsor Role collaborator

FHI 360

OTHER

Sponsor Role collaborator

RemovAid AS

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kristina Gemzell-Danielsson, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Karolinska Institutet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kawempe Referral Hospital

Kampala, , Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Uganda

References

Explore related publications, articles, or registry entries linked to this study.

Levine JP, Sinofsky FE, Christ MF; Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception. 2008 Nov;78(5):409-17. doi: 10.1016/j.contraception.2008.06.016. Epub 2008 Sep 18.

Reference Type BACKGROUND
PMID: 18929739 (View on PubMed)

Fraser IS. The challenges of location and removal of Implanon contraceptive implants. J Fam Plann Reprod Health Care. 2006 Jul;32(3):151-2. doi: 10.1783/147118906777888459. No abstract available.

Reference Type BACKGROUND
PMID: 16857065 (View on PubMed)

Creinin MD, Kaunitz AM, Darney PD, Schwartz L, Hampton T, Gordon K, Rekers H. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. Contraception. 2017 Feb;95(2):205-210. doi: 10.1016/j.contraception.2016.07.012. Epub 2016 Jul 21.

Reference Type BACKGROUND
PMID: 27452317 (View on PubMed)

Hubacher D, Byamugisha J, Kakaire O, Nalubwama H, Emtell Iwarsson K, Bratlie M, Chen PL, Gemzell-Danielsson K. Removal of a well-palpable one-rod subdermal contraceptive implant using a dedicated hand-held device or standard technique: a randomized, open-label, non-inferiority trial. Hum Reprod. 2022 Sep 30;37(10):2320-2333. doi: 10.1093/humrep/deac179.

Reference Type DERIVED
PMID: 35960174 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-103

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.